What do systematic reviews say?

ICS dose reduction vs no change

The review found no eligible studies for this question.

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

ICS dose reduction vs no change

ICS dose reduction showed no clear difference in exacerbation requiring hospitalisation compared with no change (low certainty).

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  OR 4.06 [0.45, 36.86]
  2 studies · 569 participants
  Low

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Very low

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 150 participants
  Low

ICS dose reduction vs no change

It is very uncertain whether ICS dose reduction changes steroid‐related AEs compared with no change (very low certainty).

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  OR 0.76 [0.16, 3.54]
  2 studies · 261 participants
  Very low

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 554 participants
  Very low

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 261 participants
  Low

ICS dose reduction vs no change

The review found no eligible studies for this question.

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

ICS dose reduction vs no change

• Stepping down the dose of inhaled corticosteroids for adults with asthma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 242 participants
  Low

Intervention not reported

• Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 907 participants
  High

Intervention not reported

The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).

• Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
  OR 0.6 [0.24, 1.47]
  3 studies · 1197 participants
  Low

Intervention not reported

The intervention showed no clear difference in exacerbations requiring hospital admission 49 weeks (low certainty).

• Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
  OR 0.68 [0.34, 1.38]
  3 studies · 1191 participants
  Low

Intervention not reported

• Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1191 participants
  High

Intervention not reported

• Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 907 participants
  High

Intervention not reported

The intervention leads to lower any adverse events 49 weeks (high certainty).

• Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta₂‐agonists and inhaled corticosteroids… 2016 · Cochrane Headline outcomes only
  OR 0.7 [0.52, 0.94]
  3 studies · 1197 participants
  High

Intervention not reported

The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 0.95 [0.7, 1.28]
  12 studies · 1669 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in serious adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.54 [0.81, 2.94]
  7 studies · 1343 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in total number of withdrawals (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.67, 1.37]
  7 studies · 1491 participants
  Moderate

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 526 participants
  Moderate